Want to join the conversation?
In 4Q15, $VRTX initiated Phase 2 clinical trial to evaluate VX-150, inhibitor of sodium channel known as NaV 1.8 involved in pain sensation, which is expected to enroll about 100 patients who have symptomatic osteoarthritis of knee. $VRTX expects to begin clinical development of VX-241, inhibitor of sodium channel known as NaV 1.7, in 1H16.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?